8:00 am Registration & Morning Coffee
8:55 am Chair’s Opening Remarks
Targeted Radiopharmaceuticals in the US: The Past, the Present & the Future
9:00 am Laying Out the Physical & Biological Principles: What Makes Targeted Radionuclide Therapy So Attractive
Synopsis
- Contrasting TRP against conventional external beam therapy, spotlighting toxicity, personalization, and systemic effects
- Leveraging knowledge from oncology, bioengineering, radiochemistry, and physics to navigate developing next-generation TRP agents
9:30 am Re-186 Radiolabelled NanoLiposomes for Rare Brain & Spinal Cord Tumors
Synopsis
- Exploring preclinical & clinical (Phase 1, Phase 2) data
- Applying this to notoriously-difficult to treat recurrent glioblastoma
- How effective is this for treating pediatric ependymoma & high-grade gliomas
10:00 am Speed Networking Break
Synopsis
This session is the ideal opportunity to get face-to-face time with many of the brightest minds working in the TRP field and establish meaningful business relationships to pursue for the rest of the conference.
Discovery & Translational Track
Preclinical Evaluation of Emerging Radioisotopes: From Copper to Lead
11:00 am Pb-203 Image-Guided Pb-212 Alpha Particle Therapy for Cancer – Preclinical Evidence of a Potent Paradigm
Synopsis
- Exploring the rationale behind exploring behind selecting newer isotopes
- Considering side effects and efficacy: which combinations can complement these novel isotopes to address these challenges
11:30 am Copper-67 Theranostic: Its History, Availability & Promising Future
Synopsis
- Previously limited in supply 64Cu/67Cu is a PET/beta emitting pair ideal for theranostic use
- New production technology, exclusively licensed to Iotron, has enabled commercial production quantities of high SA material without reactor-associated risks
- New studies underscore why 64Cu/67Cu diagnostic and treatment agents are gaining attention and use
11:45 am Unlocking the Potential of Theranostics
12:00 pm Small Molecule Alpha RPT Using At-211
Synopsis
- Analyzing the approaches to small molecule RPT using At-211
- Enhancing alpha therapy using a PARP-targeted platform
Clinical Track
Targets Beyond PSMA: Avoiding the Niche Label
11:00 am Development of TRP Agents Beyond PSMA & SSTR2
Synopsis
- Reviewing clinical and business cases for TRP clinical indications
- How TRP fits into the Ovarian cancer clinical pathway
- Review of l TRP data in Ovarian cancer preclinical models
11:30 am Fibroblast Activation Protein (FAP)- A Target for Imaging & Therapy
Synopsis
- Understanding the value of FAP as a target for radiopharmaceuticals
- Highlighting current clinical development efforts with FAP targeted interventions
- Reviewing SOFIE’s FAPI pipeline status
12:00 pm Choice Of Molecule & Isotope For Theranostic Indications; Exploring The Telix Pipeline
12:30 pm Lunch Break & Networking
Addressing TRP Toxicity: Chelators & Drug Design
1:30 pm Roundtable Discussion: Addressing the Key Limitation of Radiolabelled Antibodies with Pretargeting
Synopsis
- Raising the slow clearance of radiolabelled antibodies due to their size
- Designing structures that separate antibodies from radioactive agents to reduce excessive exposure to radiation
- Achieving high affinity molecules that unite and join in vivo
- Approaching this with differing dosing times – staggering administration to allow for the excess antibody to be cleared from the blood
2:00 pm Novel Approaches to Central Nervous System Targeted Radiotherapeutics
Synopsis
- Analyzing drug formulation and dosing to reduce toxicity
- Exploring local drug delivery as an administration route
- An overview of the current pipeline and where it is headed
Targeted Radiopharmaceutical Applications: Case Studies of a Variety of Indications
1:30 pm Re-186 Radiolabeled NanoLiposomes for Leptomeningeal Metastases from Solid Tumors
Synopsis
- Unpacking Preclinical and Clinical (Phase 1) Data
- Applying this to Leptomeningeal Metastases
- Planning the next steps
2:00 pm Session Reserved for Lantheus
2:30 pm Afternoon Break & Networking
Synopsis
Grab a coffee and explore our exhibition booths, network with your peers and more!
Improving the Accessibility of TRPs to Ensure That This is Treatment Available for All
3:30 pm Session Reserved for Invicro
4:00 pm How Should We Think About Commercial Aspects When Developing Radiopharmaceuticals?
Synopsis
- What indications are particularly attractive?
- How should we think about conventional competition?
- What clinical settings could be conducive for earlier line use of RPs?
4:30 pm Chair’s Closing Remarks & End of Day One
5:00 pm Poster Networking Session
Synopsis
After the formal presentations have finished for the afternoon, the learning and networking carries on. The Poster Session is allows you to connect with your peers in a relaxed atmosphere and continue to forge new and existing relationships. During this session scientific posters will be presented on the latest advancements in the TRP field.